Editorial
Copyright ©The Author(s) 2021.
World J Transplant. Feb 18, 2021; 11(2): 7-15
Published online Feb 18, 2021. doi: 10.5500/wjt.v11.i2.7
Table 1 Published articles arranged according to number of citations
Times cited
Number of manuscripts
1-10153
11-2060
21-3026
31-403
41-502
61-702
91-1001
> 1001
Table 2 World Journal of Transplantation articles cited more than 20 times
DOI
Article title
Times cited
Country
Manuscript type
Topic
10.5500/wjt.v5.i2.52Update on ischemia-reperfusion injury in kidney transplantation: Pathogenesis and treatment141ItalyReviewKidney transplantation
10.5500/wjt.v4.i2.111Human amniotic membrane transplantation: Different modalities of its use in ophthalmology96IndiaReviewMembrane transplantation
10.5500/wjt.v6.i1.69Survival of encapsulated islets: More than a membrane story63IsraelReviewOthers (post-transplantation, mechanisms, diagnosis, and management)
10.5500/wjt.v5.i4.183Cardiovascular risk factors following renal transplant61United KingdomReviewKidney transplantation
10.5500/wjt.v3.i4.48Current status of clinical islet transplantation44CanadaEditorialPancreas transplantation
10.5500/wjt.v4.i4.267Psychopathological aspects of kidney transplantation: Efficacy of a multidisciplinary team42ItalyReviewKidney transplantation
10.5500/wjt.v6.i3.451Deceased organ donation for transplantation: Challenges and opportunities37United StatesFrontierOrgan transplant donors
10.5500/wjt.v6.i1.125Post-transplant dyslipidemia: Mechanisms, diagnosis and management33CanadaReviewOthers (post-transplantation, mechanisms, diagnosis, and management)
10.5500/wjt.v4.i1.18ABO incompatible renal transplants: Good or bad?33United KingdomReviewKidney transplantation
10.5500/wjt.v6.i3.505Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders30BelgiumReviewOthers (post-transplantation, mechanisms, diagnosis, and management)
10.5500/wjt.v6.i2.291Massive haemorrhage in liver transplantation: Consequences, prediction and management30CanadaReviewLiver transplantation
10.5500/wjt.v3.i4.91Role of IL-10 in the progression of kidney disease30IsraelReviewKidney transplantation
10.5500/wjt.v6.i2.380Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience30United StatesRetrospective StudyHeart transplantation
10.5500/wjt.v2.i4.51Current state of renal transplant immunosuppression: Present and future30United StatesGuidelines For Clinical Practice Kidney transplantation
10.5500/wjt.v6.i3.517Physical rehabilitation for lung transplant candidates and recipients: An evidence-informed clinical approach29CanadaReviewLung transplantation
10.5500/wjt.v3.i4.78Exercise after heart transplantation: An overview29NorwayReviewHeart transplantation
10.5500/wjt.v3.i4.68Novel immunosuppressive agents in kidney transplantation29United StatesReviewKidney transplantation
10.5500/wjt.v2.i6.84Polyomavirus-associated nephropathy28ItalyReviewOthers (post-transplantation, mechanisms, diagnosis, and management)
10.5500/wjt.v6.i1.183Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation27SpainMinireviewsOrgan transplant donors
10.5500/wjt.v7.i3.203Developing a donation after cardiac death risk index for adult and pediatric liver transplantation27United KingdomRetrospective Cohort StudyLiver transplantation
10.5500/wjt.v6.i3.594Underutilization of palliative care services in the liver transplant population27United StatesRetrospective StudyLiver transplantation
10.5500/wjt.v5.i4.154Preservation solutions used during abdominal transplantation: Current status and outcomes27United StatesReviewOthers (post-transplantation, mechanisms, diagnosis, and management)
10.5500/wjt.v5.i2.38Changing organ allocation policy for kidney transplantation in the United States27United StatesEditorialKidney transplantation
10.5500/wjt.v5.i4.165Reducing transfusion requirements in liver transplantation26United KingdomReviewKidney transplantation
10.5500/wjt.v6.i1.91Key psychosocial challenges in vascularized composite allotransplantation25AustriaReviewVascularized composite allotransplantation
10.5500/wjt.v3.i4.99Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies25ChinaReviewStem cell transplantation
10.5500/wjt.v3.i3.36mTOR signaling in liver regeneration: Rapamycin combined with growth factor treatment25NetherlandsAutobiographyLiver transplantation
10.5500/wjt.v5.i4.209Induced pluripotent stem cells for modeling neurological disorders24BrazilReviewStem cell transplantation
10.5500/wjt.v4.i4.294Role of liver transplantation in the management of hepatoblastoma in the pediatric population24United StatesMinireviewsLiver transplantation
10.5500/wjt.v5.i2.44Philosophy of organ donation: Review of ethical facets23United StatesReviewOrgan transplant donors
10.5500/wjt.v4.i2.43Selecting suitable solid organ transplant donors: Reducing the risk of donor-transmitted infections23United StatesReviewOrgan transplant donors
10.5500/wjt.v6.i3.583Thromboelastographic reference ranges for a cirrhotic patient population undergoing liver transplantation22ItalyRetrospective Cohort StudyLiver transplantation
10.5500/wjt.v7.i3.161Biomarkers in renal transplantation: An updated review21ItalyReviewKidney transplantation
10.5500/wjt.v3.i2.7Is it time to give up with calcineurin inhibitors in kidney transplantation?21ItalyFrontier
10.5500/wjt.v6.i2.411Proposal of new expanded selection criteria using total tumor size and 18F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria21South KoreaRetrospective StudyLiver transplantation